Trana Discovery is a leading brand in the field of drug discovery technology. Founded in 2005 by scientists from North Carolina State University and senior executives from the pharmaceutical industry, Trana Discovery is uniquely positioned to be a leader in tRNA inhibition. The company specializes in exploiting the conserved region of transfer RNA (tRNA) to develop new treatments for infectious diseases.

Scientists at North Carolina State University have extensively studied the structure of tRNA, particularly the anti-codon stem loop (ASL), which is a crucial part of this complex protein. Trana Discovery has developed a proprietary discovery technology platform that enables its partners to identify potential selective candidates for the treatment of bacterial, viral, and fungal infectious diseases. By inhibiting the action of tRNA, Trana Discovery's compounds have the potential to stop the replicative cycle of pathogens, leading to the development of new drugs for the treatment of human and animal diseases.

With a highly experienced management team, including industry veterans with over 300 years of collective experience, Trana Discovery is committed to addressing the growing need for effective treatments for infectious diseases. Their innovative approach and expertise in tRNA inhibition position Trana Discovery as a key player in the field